Anti-Rheumatic Drugs - Asia

Asia

The Asian market for Anti-Rheumatic Drugs market is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is estimated to reach US$6.31bn by the year 2024.
Furthermore, it is anticipated that the market will continue to grow at an annual growth rate of 1.13% (CAGR 2024-2028), resulting in a market volume of US$6.60bn by 2028.
When compared to the global market, United States is expected to generate the highest revenue, with an estimated amount of US$37,550.00m in 2024.
This showcases the dominance of the US market in the Anti-Rheumatic Drugs market.
In Japan, there is a growing demand for biologic anti-rheumatic drugs due to their higher efficacy and better safety profile compared to traditional disease-modifying anti-rheumatic drugs.

Key regions: France, Italy, Brazil, China, India

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Rheumatic Drugs in Asia has been steadily increasing over the years due to various factors.

Customer preferences: Patients suffering from rheumatoid arthritis, osteoarthritis, and other rheumatic diseases are the primary consumers of Anti-Rheumatic Drugs. These patients prefer drugs that provide relief from pain and inflammation and prevent joint damage. They also prefer drugs that have fewer side effects and are affordable.

Trends in the market: In China, the Anti-Rheumatic Drugs market has been growing due to the rising prevalence of rheumatic diseases in the country. The market is also being driven by the increasing demand for biologics and biosimilars. In India, the market is expected to grow due to the increasing adoption of advanced therapies and the rising geriatric population. The Japanese market is also expected to grow due to the increasing prevalence of rheumatic diseases and the launch of new drugs.

Local special circumstances: In Southeast Asia, the Anti-Rheumatic Drugs market is expected to grow due to the increasing awareness about rheumatic diseases and the availability of affordable drugs. In South Korea, the market is being driven by the increasing adoption of biologics and the launch of new drugs. In Taiwan, the market is expected to grow due to the increasing prevalence of rheumatic diseases and the launch of new drugs.

Underlying macroeconomic factors: The rising prevalence of rheumatic diseases in Asia is a major driver of the Anti-Rheumatic Drugs market in the region. The increasing geriatric population in many Asian countries is also contributing to the growth of the market. The rising disposable income and increasing healthcare expenditure in the region are also driving the demand for Anti-Rheumatic Drugs. Additionally, the increasing adoption of advanced therapies and the launch of new drugs are expected to boost the growth of the market in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.